Summary: Chronic wounds represent a significant medical burden. Such wounds fail to normally progress through the stages of healing, often complicated by a proinflammatory milieu caused by increased proteinases, hypoxia, and bacterial burden. As a result, several modalities, such as dressings, antimicrobials, growth factors, and human skin substitutes, have been devised in an attempt to correct the chronic wound environment. This review addresses these modalities with a focus on evidence and randomized controlled trials. (Plast.
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hronic wounds are a medical challenge, costing the U.S. health system over $25 billion dollars per year. 1 Leg ulcers alone affect upward of 2.5 million Americans, with 2 million workdays lost per year. 2 Two-thirds of patients report negative emotional impact directly attributable to their ulcer, illustrating the necessity for proper wound care. 3 Although the causes of chronic wounds are numerous, diabetic, arterial, venous, and pressure ulcers constitute the majority of chronic wounds. Despite unique pathophysiology, factors contributing to chronicity of nonhealing wounds become similar with time 4 ( Fig. 1 ).
BIOLOGY OF CHRONIC WOUNDS
Wound healing is a dynamic process of three overlapping phases: inflammation, proliferative phase with granulation tissue formation and epithelialization, and tissue remodeling. 5, 6 Inflammation lasts several days in the acute healing wound but persists in the chronic wound. 7 Driven by proinflammatory cytokines, 8 -10 the prolonged and overactive neutrophil response leads to increased protease activity, mainly matrix metalloproteinases. 11, 12 In some cases, protease activity has been found to be over 100 times higher in chronic compared with acute wounds. 13 Increased metalloproteinases lead to degradation of growth factors, their receptors, 11 and adhesion proteins, such as fibronectin and vitronectin, 14 preventing cell adhesion for normal wound closure. 11, 13, 15 As a result, topical treatments aimed at inflammation and excess proteases have been developed.
Wounding damages the blood supply, leading to hypoxia, 16 along with subsequent decreased oxidative bursts and microbicidal activity by polymorphonuclear leukocytes. 17, 18 The uncontrolled polymorphonuclear leukocytes respond to low oxygen tension by releasing proteinases and toxic oxygen metabolites, which damages endothelial cells, leading to cellular destruction, deposition of fibrin, and further decreased delivery of nutrients and oxygen, propagating a vicious cycle. 16 Systemic disorders, such as decreased cardiac output, smoking, peripheral vascular disease, past irradiation, and chronic infection, all contribute to hypoxia in the local environment. 15 Reperfusion injury plays a role. During ischemia, substances such as hypoxanthine and xanthine oxidase are made. Reperfusion causes oxygen to react with these substances, producing superoxide bursts that further damage the endothelium. 19 The inflammatory state is also prolonged by the presence of bacteria, 20 leading to increased metabolic demand and protease levels in the wound. 21 The mere presence of bacteria in chronic wounds does not affect healing. 22 Definitions used for overt, clinical infection include microorganism density greater than 10 5 to 10 6 colony-forming units/g, as these levels are used as a threshold for delayed wound healing and disease. [23] [24] [25] Symptoms such as
DRESSINGS
Two general categories of wound dressing exist. 21 Passive wound dressings mainly control wound moisture levels. The synthetic polymers in dressings afford customization in terms of absorbency, physical form, and gas permeability (Table 1) . 29 -37 Active dressings locally alter the wound's biochemical environment. 21 
Passive Dressings
The rationale for occlusive dressings is often traced to 1962, when Winter observed that moisture-retaining dressing speeds epithelization of acute, superficial compared with air-exposed wounds in pigs. 38 The following year, Hinman and Miabach published results in humans demonstrating similar results. 39 The benefits of occlusion in partial-thickness wounds are numerous. Without the impediment of the crust seen in dry wounds, the wet dermal surface provides a superior medium for epidermal cells to migrate. 40 Eaglstein and Mertz demonstrated that occlusion accelerates epithelialization in the acute split-thickness wound by 40 percent. 41 Acute wound fluid under the occlusive bandage contains substances, such as growth factors, that stimulate proliferation of fibroblasts and endothelial cells, 42, 43 promoting granulation tissue formation. Depending on the type, occlusive dressings can also manage exudates (Table 1) . 45, 46 Randomized trials have demonstrated increased speed and less painful healing in acute, superficial wounds compared with nonocclusive modalities. 47, 48 An increased rate of healing has been observed when dressings are placed within 2 hours of injury and kept on for at least 24 hours. 49 Theoretically, a moist environment provides a good environment for bacterial colonization and possibly infection, which can be an impedance to applying occlusion. This has not been shown to be true: occlusion actually provides a barrier against infection and reduces infection rates. 23, 34, 36, 50 Although partial-thickness healing is faster under occlusion, it is less clear whether occlusive dressings speed acute, full-thickness wound healing. 48 In the absence of wound site disease, full-thickness wounds will eventually heal by means of secondary intention. 51 Although some experimental data in pigs suggest complete healing is faster with occlusive dressings in full-thickness wounds versus nonocclusive therapy, 52, 53 the speed at which epithelialization occurs and concomitant contractures are often not optimal or desirable in patients. Most clinicians will opt for grafts or flaps instead.
Similarly, the effect of occlusion on chronic wounds has not been fully elucidated, as evidence is mixed. It has been demonstrated that chronic wound fluid under occlusive dressings actually inhibit cell proliferation in vitro 54 by restricting entry into the S phase and DNA production, 55 and degradation of adhesion proteins. 14 Despite this, there are many reasons to justify the use of occlusion in chronic wounds. It has been shown to facilitate painless and effective autolytic débridement, 56 which is the use of enzymes within the wound fluid to remove necrotic debris. 36 Occlusion reduces cost because of less frequent dressing changes compared with standard gauze. 57, 58 Furthermore, the same principles of pain reduction, 40, 58 exudate management, and safety 59 with the use of occlusive dressings apply in the chronic wound.
Currently, dressing modalities are chosen mostly based on opinion, as high-level evidence is conflicting. 60, 61 Although some meta-analyses have demonstrated benefits of occlusive dressings in the treatment of pressure ulcers 62 and chronic wounds, 32, 63 other authors have found insufficient evidence to recommend modern dressings for pressure ulcers, 64, 65 arterial leg ulcers, 29 chronic leg ulcers, 66 venous ulcers, 30, 67 or surgical wounds healing by secondary intention. 61, 68 The lack of effective animal models available for study 69 and Plastic and Reconstructive Surgery • January Supplement 2011
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level I evidence makes providing evidence-based recommendations difficult. 29, 30, 32, 66 Awaiting better evidence, dressing choices should be based on clinical experience. 70, 71 Ease of use, patient preference, amount of wound drainage, and protection against bacteria should all be taken into consideration (Table 1) . 30, 64, 72 A moist yet absorbent environment needs to be maintained, avoiding wound maceration or dehydration. 30, 70, 71, 73, 74 Dressings should minimize external forces such as friction and sheer and should stay in place. 70, 71 Fear of maceration and its potential complications in certain wound types suggest completely occlusive and highly adhesive dressings should be avoided in diabetic foot ulcer, 75 and hydrogels should be used instead.
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Active Dressings
Interest in development of active dressings stems from the altered biology of the chronic wound ( Table 2) . 27, 34, 68, 77 Potential targets include increased bacterial load and excessive protease levels, which lead to the development of antimicrobial, protease inhibitor, 76 and collagen dressings. 21 The combination of antimicrobials with the dressings described above affords bacterial reduction and maintains a moist environment.
Collagen Dressings
Collagen has long been known to have a critical function in wound healing, providing platelet aggregation; hemostasis; and chemotaxis of macrophages, granulocytes, and fibroblasts. 78 It was rationalized that exogenous collagen matrices might provide a scaffold for tissue ingrowth when endogenous collagen is disrupted by the proteolytic wound environment. 21 In addition, dressings containing oxidized regenerated cellulose bind the high level of proteases seen in chronic wounds, protecting growth factors from destruction and neutralizing free radical damage. 79, 80 However, randomized controlled trials of 55 percent bovine collagen to 44 percent oxidized regenerated cellulose dressing (Promogran wound matrix; Systagenix, North Yorkshire, United Kingdom) did not demonstrate significantly better wound closure of Wagner grade I or II diabetic foot ulcers 81 or venous leg ulcers, 82 although variability of loading (for the former study) and dressing change procedure might have negatively affected these results.
Another collagen dressing comprised of porcine-derived acellular small intestine submucosa (Oasis Wound Matrix, Fort Worth, Texas) was found to be equivalent to recombinant human plateletderived growth factor (rhPDGF)-BB in diabetic ulcers (see below) (becaplermin, Regranex; Systagenix, Commonwealth, Mass.). 83 The dressing was found to improve healing in full-thickness diabetic ulcers 84 and mixed vascular ulcers 85 when compared with standard-of-care treatment at 12 weeks and petroleum gauze at 8 weeks, respectively.
TOPICAL ANTIMICROBIALS
The ideal antimicrobial exists in an equilibrium whereby bacteria bioburden is reduced without interfering with cellular processes by means of cytotoxicities. 16, 20, 86 Although antibiotics have specific sites of activity, antimicrobials have a lower incidence of resistance and multiple sites of activity, and target a wide variety of bacteria, protozoa, fungi, viruses, and prions. 16, 20, 87 The most commonly used products include chlorhexidine, povidone-iodine, cadexomer iodine, alcohol, acetate, hydrogen peroxide, boric acid, silver sulfadiazine (an antibiotic), silver nitrate, and sodium hypochlorite (Table 3) . 26,45,88 -106 Iodophors, a class of antiseptic including povidone-iodine and cadexomer iodine, are slowrelease carriers designed to curb elemental iodine toxicity. 87 Most in vitro studies suggest that povidone-iodine is toxic to the cells that participate in wound healing. In vivo studies have not found that it promotes good wound healing. 91, 107 However, evidence exists suggesting cadexomer iodine, compared with standard-of-care regimens, results in significantly higher complete venous ulcer healing rates. 96 It is also more cost effective, results in less infection, and has fewer adverse effects than hydrocolloids or paraffin gauze. 97 Silver compounds, particularly silver nitrate and silver sulfadiazine, have been used widely in burns. The reactivity of silver compounds with negative substances such as DNA, RNA, proteins, and components of the electron transport system is the heart of its antimicrobial effect. 87 Such reactivity requires a carrier for consistent slow delivery to balance the cellular toxicity against the microbicidal activity.
Moyer et al. found that 0.5% silver nitrate administered on gauze dressing achieved such balance. 102, 108 However, silver nitrate darkens tissue, causes hyponatremia and hypochloremia, and has been shown to be systemically absorbed. 103 The very frequent applications, up to 12 times per day, results in a large excess of silver at the wound site. 109 Furthermore, nitrate is converted to nitrite, an oxidant capable of cell damage.
The advent of silver sulfadiazine, created from the combination of silver nitrate and sodium sulfadiazine, allowed for better delivery of silver, allowing Volume 110, 111 Since then, silver sulfadiazine gauze has been used widely as an antibiotic in the topical treatment of second-to third-degree burns. Nanocrystalline silver dressings represent further modification in prolongation of silver delivery. 109 With sustained release of silver in a less rapidly deactivated form, daily or weekly dressing change with steady silver release can be achieved.
Despite large bodies of research on the benefits of silver therapeutics, much less evidence regarding the effect of silver ion on the wound bed exists. 109 In vitro, silver has been shown to delay wound healing when compared with tulle gras dressing by means of toxicity to keratinocytes and fibroblasts. 112 In vivo, a similar delay in healing exists with partial-thickness burns treated with silver sulfadiazine. 113 Two recent Cochrane reports found little evidence to support use of silver sulfadiazine in burn wounds or silver-containing dressing in wounds because of a lack of clinical proof of wound infection prevention or increased rate of healing. 104, 105 As with occlusive dressings, a lack of high-quality evidence exists. 68, 114, 115 Recommendations are often based on expert opinion or personal preference. 94 Topical antiseptics should be reserved for signs of bacterial burden detrimental to healing as evidenced by clinical signs (described above) or by failure to heal to avoid possible cytotoxicity. 20, 21, 109 
GROWTH FACTORS
In a series of elegant experiments, Cohen noticed that the purification of submaxillary gland extracts led to earlier eyelid separation and eruption of the incisor in mice, which eventually led to the isolation of the first growth factor, epidermal growth factor, and the 1986 Nobel Prize in Medicine.
116 Since Cohen's discovery, knowledge of growth factors has increased. In the acute wound, growth factors function in a paracrine, autocrine, intercrine, or endocrine manner, stimulating healing. 15 However, in the chronic wound, the balance between stimulation and inhibition is lost, as growth factors and their receptors are destroyed, 15, 117 trapped, 118 or maldistributed in the chronic wound. Fibroblasts have also been reported to be less responsive to growth hormone, likely secondary to senescence.
119
Platelet-Derived Growth Factor
Currently, rhPDGF-BB is the only growth factor approved by the U.S. Food and Drug Administration for use in chronic wounds (Table 4) . [121] [122] [123] Becaplermin is rhPDGF-BB produced by the yeast Saccharomyces cerevisiae. The BB isoform is the only one of the three (PDGF-AA, PDGF-AB, and PDGF-BB) that has been shown to bind to both alpha and beta receptors. 120 Prepared as a topical gel, becaplermin has been approved for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply (stage III or IV).
A meta-analysis of 922 patients among four trials of rhPDGF-BB in full-thickness, nonhealing, lower extremity diabetic ulcers found that becaplermin with good wound care leads to a significant increase in complete healing when compared with placebo. 121 Among the studies included in the metaanalysis, Steed found that patients (n ϭ 118) treated with rhPDGF-BB compared with placebo achieved significantly higher complete wound healing rates when evaluated at 20 weeks. Although not statistically significant, there was a greater recurrence rate in placebo (46 percent) compared with rhPDGF-BB (26 percent). 124 This trial was the first to demonstrate that topical application of a single growth factor could speed healing of a chronic wound. In a pivotal trial, Wieman et al. found that patients (n ϭ 382) treated with 100 g/g of becaplermin gel experienced significantly increased complete diabetic lower extremity ulcer closure compared with placebo-treated patients. 125 Despite the impressive findings, becaplermin has recently received a new black box warning from the U.S. Food and Drug Administration. Although no increase in incidence of cancer was found, there was an increased mortality secondary to malignancy in those using three or more tubes. 122 The U.S. Food and Drug Administration does not recommend becaplermin for those with known malignancies. However, longer follow-up of those patients in the original report found that the increase in mortality among the becaplermintreated group did not persist. 126 Epidermal growth factor and macrophage colony-stimulating factor are being examined for use in wound healing. 127, 128 Although initial results were promising, fibroblast growth factor-2 has had its production discontinued.
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ENGINEERED LIVING SKIN
Despite use of standard of care and advanced topical treatments, some wounds fail to improve. 130 Plastic and Reconstructive Surgery • January Supplement 2011
52S
Another topical therapy, engineered skin, is an option (Table 5) . Engineered skin was initially envisioned to treat burn wounds when autologous grafts were unavailable. 131 However, skin substitutes have received wider applications in chronic venous 132 and diabetic 133, 134 wounds, stimulating healing through a variety of potential mechanisms. Two major classes of cellular engineered skin are currently used in the United States: dermal and bilayered constructs.
132-144
Cellular Dermal Constructs
As a living dermal substitute, human fibroblastderived dermal substitute is created by seeding fibroblasts derived from neonatal foreskin onto a bioabsorbable polyglactin matrix (Dermagraft; Advanced BioHealing, Inc., La Jolla, Calif.). 146 The fibroblasts secrete adhesion molecules and growth factors as epithelialization occurs over the dermal bed replacement. 143, 147, 148 Dermagraft was found to result in a faster and higher percentage of complete healing in full-thickness, chronic (Ͼ6 weeks) diabetic ulcers compared with conventional therapy.
133
Bilayered Constructs
The bilayered construct is composed of living keratinocytes for epidermis and fibroblasts derived from neonatal foreskin, placed within a bovine type 1 collagen matrix for dermis. 149 Apligraf (Organogenesis, Canton, Mass.) is designed to resemble skin, with cells producing a milieu of growth factors, collagen, and extracellular matrix proteins to promote reepithelialization, granulation tissue formation, and angiogenesis, while providing protection against infection. 132, 145, 150, 151 In randomized controlled trials, Apligraf achieved a significantly faster and higher rate of complete healing in venous ulcers 132, 152 and diabetic foot ulcers, 134 with lower incidences of osteomyelitis and amputations in the latter disease compared with the standard of care.
ENGINEERED ACELLULAR SKIN: ACELLULAR DERMAL SUBSTITUTES
In addition to cellular constructs, acellular constructs have been developed primarily for burn wounds. One such product is AlloDerm (LifeCell Corp., Branchburg, N.J.), a cadaveric skin processed to remove cellular and antigenic components, leaving an acellular dermal matrix with an intact basement membrane complex. 138 It has seen use in burns, 139 abdominal wall reconstruction, 153 and breast reconstruction, 154, 155 to name a few. 
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Another approach is to use acellular bovine collagen matrices with shark-derived chondroitin sulfate matrices bonded to a temporary Silastic epidermis (Integra; Integra LifeSciences Corp., Plainsboro, N.J.). 140 Along with serving as a conduit for growth factors and angiogenesis, these acellular matrices serve as a transient biodegradable scaffold as a new dermis is regenerated. 143 Integra provides temporary covering when immediate grafting is not possible. Studies have shown that Integra has similar graft take compared with nonautograft controls in wounds with a large body surface area, but with better patient satisfaction, less hypertrophic scarring, 135 and shorter hospital stays. 156 Moiemen et al. demonstrated Integra's use in reconstructive surgery, especially in contracture and scar repair, with patients reporting improvement in range of motion, softness, and appearance.
